RecruitingPHASE1, PHASE2NCT07439887

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Studying Stargardt disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ray Therapeutics, Inc.
Intervention
RTx-021(genetic)
Enrollment
18 target
Eligibility
16 years · All sexes
Timeline
20262030

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07439887 on ClinicalTrials.gov

Other trials for Stargardt disease

Additional recruiting or active studies for the same condition.

See all trials for Stargardt disease

← Back to all trials